# Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients

Study · id `cardio:ct-nct02244879` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02244879](<https://clinicaltrials.gov/study/NCT02244879>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT02244879

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.

## Technical summary

Registry record NCT02244879. Randomized; triple masking; primary purpose treatment. Start 2013-10 (registry gives no type); primary completion 2016-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; triple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 192 participants (enrolled count; ClinicalTrials.gov record NCT02244879, source copy `cardio:ctgov-nct02244879-2016-03-08`, retrieved 2026-10-26)
- Start date: 2013-10 (registry gives no type) (ClinicalTrials.gov record NCT02244879, source copy `cardio:ctgov-nct02244879-2016-03-08`, retrieved 2026-10-26)
- Primary completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02244879, source copy `cardio:ctgov-nct02244879-2016-03-08`, retrieved 2026-10-26)
- Completion: 2016-02 (actual) (ClinicalTrials.gov record NCT02244879, source copy `cardio:ctgov-nct02244879-2016-03-08`, retrieved 2026-10-26)
- Countries: Italy (ClinicalTrials.gov record NCT02244879, source copy `cardio:ctgov-nct02244879-2016-03-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02244879-2016-03-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Effects of Resveratrol on Inflammation in Type 2 Diabetic Patients
- Condition: Type 2 Diabetes Mellitus
- Condition: Inflammation
- Condition: Insulin Resistance
- Condition: Other Disorders of Bone Density and Structure
- Intervention (Dietary supplement): resveratrol
- Lead sponsor: University of Turin, Italy
- Lead sponsor class: OTHER
- Collaborator: Ministry of Health, Italy
- Collaborator class: OTHER\_GOV

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: University of Turin, Italy (`cardio:org-university-of-turin-italy`)
- Registry lists this organization as a collaborator: Ministry of Health, Italy (`cardio:org-ministry-of-health-italy`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Effects of 6 months of resveratrol versus placebo on pentraxin 3 in patients with type 2 diabetes mellitus: a double-blind randomized controlled trial (`cardio:pubmed-28238190`)
- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Impact of sirtuin-1 expression on H3K56 acetylation and oxidative stress: a double-blind randomized controlled trial with resveratrol supplementation (`cardio:pubmed-29330620`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 3f13e8818d479e95b8161e4022ebad528e20e63c76305ab2a087f1fe5686c342
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
